Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda” |
| |
| Authors: | Alfredo Molteni Marta Riva Annamaria Pellizzari Lorenza Borin Alessandra Freyre Rosa Greco Marta Ubezio Massimo Bernardi Alessio Fariciotti Guido Nador Michele Nichelatti Emanuele Ravano Enrica Morra |
| |
| Affiliation: | 1. Department of Hematology, AO Ospedale Niguarda Ca’ Granda, Milan, Italy;2. Department of Hematology, Spedali Civili di Brescia, Brescia, Italy;3. Department of Hematology, S. Gerardo Hospital, Monza, Italy;4. Department of Hematology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;5. Department of Hematology, Fondazione IRCCS S. Matteo, Pavia, Italy;6. Department of Hematology, San Raffaele Scientific Institute, Milan, Italy;g Oncology-Hematology Unit, Ospedale di Rho. AO Salvini, Rho, Italy;h General Medicine Unit, AO Ospedale Civile di Legnano, Legnano, Italy;i Service of Biostatistics, Department of Hematology, AO Ospedale Niguarda Ca’ Granda, Milan, Italy |
| |
| Abstract: | ![]()
To analyze the unpredicted event of hematological improvement (HI) during iron-chelation therapy (ICT), we reviewed a series of 53 myelodysplastic patients with transfusion dependency in a retrospective study involving 8 centers afferent to the “Rete Ematologica Lombarda”. According to the IWG response criteria published in the year 2000, we observed erythroid responses in 19 patients (35.1%), 5 major (9.2%) and 14 minor (25.9%). In the assessable patients, platelet response was 8/13 (61%) and neutrophil response was 13/17 (76.4%). Only in patients with erythroid improvement, multilineage responses were observed. Apparently, patients with greater erythropoiesis dysfunction may take more advantage. |
| |
| Keywords: | Iron-chelation therapy Hematological improvement Myelodysplastic syndromes |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
